Drug intelligence / Profile preview

Lentiviral Ciliary Neurotrophic Factor (LV-CNTF)

Development stage
Preclinical
Modality
Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration
Intravitreal, Subretinal
01

Overview

Lentiviral Ciliary Neurotrophic Factor (LV-CNTF) is a gene therapy approach that utilizes a lentiviral vector to deliver the gene encoding Ciliary Neurotrophic Factor (CNTF). CNTF is a neurotrophic cytokine that plays a crucial role in promoting the survival, differentiation, and function of neurons, particularly photoreceptors and retinal ganglion cells. Upon successful gene transfer and expression, the secreted CNTF protein binds to its specific receptor complex, which consists of Ciliary Neurotrophic Factor receptor alpha (CNTFRα), Leukemia inhibitory factor receptor beta (LIFRβ), and Glycoprotein 130 (gp130). This binding event activates intracellular signaling pathways, primarily the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, specifically STAT3, and the MEK-ERK pathway, leading to neuroprotective effects. LV-CNTF has been investigated in preclinical studies for its potential to treat various retinal degenerative diseases by preserving retinal cells.

Other names
CNTF gene therapy (lentiviral vector)
02

Targets

IL-6R (Interleukin-6 receptor subunit alpha)LIFR (Leukemia inhibitory factor receptor)IL6ST (Interleukin-6 receptor subunit beta)

Beyond the preview

Go deeper on Lentiviral Ciliary Neurotrophic Factor (LV-CNTF).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lentiviral Ciliary Neurotrophic Factor (LV-CNTF).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call